INTRATHECAL BAR THERAPY FOR MALIGNANT BRAIN TUMORS Kintomo Takakura 1 , Masao Matsutani 1 , Yasuo Koyama 2 , Oei Kiem Sing 3 1National Cancer Cencer Hospital, Department of Neurosurgery 2National Cancer Center Hospiatl, Department of Neurology 3University of Tokyo Hospital, Department of Neurosurgery pp.585-593
Published Date 1972/5/1
DOI https://doi.org/10.11477/mf.1406203117
  • Abstract
  • Look Inside

Intrathecal BAR (BUdR-Antimetabolite-Radia-tion) therapy was applied to 21 cases of malignant brain tumors (pineoblastoma 2, pinealoma 2, ectopic pinealoma 2, unverified 3rd ventricular tumor 2, glioblastoma 1, oligodendro-ependymoma 1, menin-gosarcoma 1, retinoblastoma 1 and metastatic cancer 7 cases). Ficon tube (2 mm outer diameter) wasinserted either intraventricle or in local dead space of the tumor removed. (1) Bromouridine (BUdR), 50-150 mg/d as radiosensitizer, (2) Methotrexate, 0.3-1.5 mg/d or Mitomycin C, 0.3-0.5 mg/d as chemotherapeutic drug and (3) Dextran sulfate-lysosome labilizer-(MDS), 50-150 mg/d for intensi-fying the tumoricydal effect of chemotherapeutic drugs were combined and disolved in saline. Con-tinuous intrathecal infusion was carried out by using portable chronofuser for 2 to 6 weeks ac-companied with radiation therapy (ultra-high vol-tage X-ray). Effects of the therapy was evaluated by clinial improvements X-rav examinations orany other possible examinations. Long term survi-val was evaluated espescially on the basis of pos-sibility of normal social life of the patients. Among 21 cases, 14 were quite effective, a case of medul-loblastoma showed no effect and 6 other cases can not be fully evaluated the effectiveness at the moment. The merits of this intrathecal BAR therapy are safety and easiness of the treatment, compared to the intraarterial BAR therapy. The indication of the method is for intraventricular, multiple and disseminated tumors.

Copyright © 1972, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 2185-405X 印刷版ISSN 0006-8969 医学書院